Physicians may now be better at detecting breast cancer than ever before, but much more work remains to ensure accurate diagnosis is possible and especially to assess future risk. That's why researchers from Germany have been working to develop a new test of gene action to predict cancer risk both at first diagnosis and into the future. In a new research report appearing in the December 2012 issue of The FASEB Journal, researchers show that the various genetic switches, which are turned on and off in the regular development of every cell in the body, can be analyzed in minute detail to determine the presence or risk of breast cancer growth.
"We hope that our results help to develop tools to identify breast cancer patients when tumors are still small, and eventually curable," said Clarissa Gerhauser, Ph.D., a researcher involved in the work from the Division of Epigenomics and Cancer Risk Factors at the German Cancer Research Center in Heidelberg, Germany. "These tools might hopefully also help to predict the progression of tumor development and guide decisions on cancer treatment."
To make this advance, Gerhauser and colleagues extracted DNA from 10 small tumor tissue samples and 10 normal breast tissues from breast cancer patients. They made small fragments from the extracted DNA and identified the genetic switches within those fragments. By comparing the results from various combinations of DNA fragments, scientists discovered which switches were more prevalent in tumor tissue than in normal breast tissue. The methods used to quantify the switches are extremely sensitive, making it feasible that small biopsies would be sufficient for analysis and testing.
"This is a milestone. The method described detects activity at the genetic level, which often occurs well before any outward symptoms occur," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Not only could this allow for earlier diagnosis of breast cancer and more accurate risk assessment, but eventually, this technique might be used in other types of cancer as well."
Federation of American Societies for Experimental Biology: http://www.faseb.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Ah, motherhood. I don’t know anything about it, but I heard there’s a lot of, like, sacrifice and stuff. Not only do you have to bring the brat into the world, but then you have to feed it for at least 18 years or you get in big trouble. That’s a lot of pressure.
It’s three in the morning in South Africa, in the middle of winter. Temperatures have dropped to just …
A jellyfish tagging study reveals the creatures' ability to swim against the current when forming their submarine swarms, say researchers.
Size isn't everything. When many male mice mate with the same females, their descendants evolve testes that can produce more sperm
Along the seashore, harmful blooms caused by an organism called Sea Sparkle choke ecosystems but look positively enchanting
The opposable thumb you use to hold a pencil was long thought to be a defining aspect of humans. But an analysis of finger bones suggests stone tool use by pre-humans — perhaps 3 million years ago.
Blind since birth, Julee-anne Bell wasn't comfortable heading out on her own. And when she learned an echolocation technique that gave her more independence, she discovered that it came with costs.
In tight times, cuts urged for ocean observing network and ships
By making E. coli dependent on an artificial amino acid, scientists hope to show that engineered organisms can be safer and more useful for industrial processes like drug production.
The frilled shark's roots are traced to 80 million years ago. Its prehistoric origins are obvious in its primitive body; nearly all of the rare animal's closest relatives are long extinct.